A pioneering Phase 1 clinical trial, reported in a March 9, 2025, ScienceDaily article, is advancing stem cell therapies for Parkinson's disease. After over 30 years of research, the trial reprograms ...

The licensed technology was part of the first FDA approved trial to test mesenchymal stem cell derived exosomes in cancer patients. The company's first commercial product, ExoWELL™, is a ...

Say goodbye to hair loss with exosome therapy Explore how exosomes work to stimulate hair follicles and enhance hair density ...

While the trial focuses on stem cell transplantation, it hints at broader mechanisms—like exosome release—that could transform Parkinson's care by repairing brain damage and enhancing dopamine ...

RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the ...

Currently, doctors do not treat breast cancer patients with obesity-driven diabetes any differently than those without ...

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.

About PranaX Corporation PranaX is a regenerative medicine biotechnology company dedicated to harnessing stem cell-derived exosomes to rejuvenate aging, inflamed, and damaged tissues and organs ...